Sehhoon Park

发表

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2022, Cancer medicine.

DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2019, Lung cancer.

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer

Dong-Wan Kim, D. Heo, Ji-yeon Kim, 2017, The Korean journal of internal medicine.

Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer

Jeong Eon Lee, J. Lee, J. Ahn, 2020, Molecular Cancer Research.

A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer

Su Jin Lee, S. J. Lee, M. Ahn, 2021, Cancer research and treatment.

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Immunotherapy for Cancer.

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer.

Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.

J. Ahn, M. Ahn, Yoon-La Choi, 2022, European journal of cancer.

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study

J. Ahn, M. Ahn, Yoon-La Choi, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Case of Statin-Induced Interstitial Pneumonitis due to Rosuvastatin

Se Jin Kim, C. Ock, Seung Wook Hong, 2015, Tuberculosis and respiratory diseases.

Metabolic parameters on baseline 18F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma

Kyung-Han Lee, J. Choi, M. Ahn, 2022, Frontiers in Medicine.

FP03.02 Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)

B. Cho, C. Lee, H. Yoon, 2021 .

Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

M. Ahn, Se-Hoon Lee, H. Jung, 2022, PloS one.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.

Joungho Han, Jong-Mu Sun, Sehhoon Park, 2019, Lung cancer.

Evaluating entrectinib as a treatment option for non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Expert opinion on pharmacotherapy.

Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma

Joungho Han, Yoon-La Choi, Se-Hoon Lee, 2022, Cancer research and treatment.

EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, iScience.

Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study

J. Ahn, M. Ahn, Yoon-La Choi, 2022, Precision and Future Medicine.

Lung Cancer in Korea.

Ho Yun Lee, Hyae-Young Kim, Yoon-La Choi, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, Cancer medicine.

Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.

J. Ahn, M. Ahn, Keunchil Park, 2022, International journal of radiation oncology, biology, physics.

Prognostic value of p21‐activated kinase 4 in resected pancreatic cancer

Yoo-Seok Yoon, J. W. Kim, Keun-Wook Lee, 2017, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

Donggeun Yoo, J. Ahn, M. Ahn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment

J. Ahn, M. Ahn, Se-Hoon Lee, 2023, Journal for ImmunoTherapy of Cancer.

Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal for ImmunoTherapy of Cancer.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor

Seunggyun Ha, Dong-Wan Kim, D. Heo, 2018, PloS one.

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

Dong-Wan Kim, D. Heo, B. Keam, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB‐4 liver fibrosis index

B. Cho, D. Shin, Hyung-kook Yang, 2015, Cancer.

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.

J. Ahn, M. Ahn, Keunchil Park, 2021, European journal of cancer.

High liver fibrosis index FIB‐4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers

B. Cho, D. Shin, S. Yu, 2015, Hepatology.

Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist’s Perspective

Sehhoon Park, 2023, Journal of chest surgery.

Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer

M. Ahn, W. Park, Chung Lee, 2021, BMB reports.

Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR

S. Kim, M. Ahn, Hyung-Jin Kim, 2020, Journal of Neuro-Oncology.

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Early repolarization is associated with significant coronary artery stenosis in asymptomatic adults.

B. Cho, D. Shin, Seung‐Pyo Lee, 2016, Atherosclerosis.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations

Dong-Wan Kim, D. Heo, B. Keam, 2016, The Korean journal of internal medicine.

Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma

Se-Hoon Lee, Hyunju Lee, Sehhoon Park, 2017, BMC Cancer.

Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

M. Ahn, Yoon-La Choi, Jong-Mu Sun, 2022, Cancer.

Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Clinical Oncology.

Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy

Y. Jung, Haeryoung Kim, Jin Hyun Park, 2016, Medicine.

Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells

J. Ahn, M. Ahn, H. Cha, 2023, Advanced science.

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis

Y. Heo, Sehhoon Park, Jaeyun Jung, 2023, Journal for ImmunoTherapy of Cancer.

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

J. Ahn, M. Ahn, Keunchil Park, 2020, Biology.

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer.

Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.

M. Ahn, Keunchil Park, Y. Shim, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.

M. Ahn, Keunchil Park, Se-Hoon Lee, 2021 .

Mild form of Guillain-Barré syndrome in a patient with primary Epstein-Barr virus infection

C. Ock, K. Choe, Seung Wook Hong, 2016, The Korean journal of internal medicine.

In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.

Keunchil Park, Se-Hoon Lee, Sehhoon Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor in non-small cell lung cancer.

T. Mok, C. Ock, Se-Hoon Lee, 2020 .

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer research and treatment.

The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2021 .

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

J. Ahn, M. Ahn, Keunchil Park, 2023, JAMA network open.

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Translational lung cancer research.

Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early‐stage lung adenocarcinoma

M. Ahn, Y. Shim, Soohyun Hwang, 2023, Histopathology.

Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2020 .

Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

First-Line Alectinib vs. Brigatinib in Advanced NSCLC with ALK Rearrangement: Real-World Data.

J. Ahn, M. Ahn, Jong-Mu Sun, 2023, Cancer research and treatment : official journal of Korean Cancer Association.

Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings

J. Ahn, Keunchil Park, Soohyun Hwang, 2020, Stroke and vascular neurology.

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

M. Ahn, Keunchil Park, H. Jung, 2023, Cancer research and treatment.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor

Seunggyun Ha, Dong-Wan Kim, D. Heo, 2018, PloS one.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

J. Ahn, M. Ahn, Keunchil Park, 2023, Cancer research and treatment.

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP

Sheehyun Kim, K. Jang, J. Cheon, 2023, Cancer research and treatment.

A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2023, Cancer.

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer.

J. Ahn, M. Ahn, Soohyun Hwang, 2023, Journal of Thoracic Oncology.

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

Hye Hyeon Eum, Jong-Mu Sun, J. Cho, 2024, bioRxiv.

Increasing discrepancy of MR imaging and CSF study in patients with leptomeningeal seeding from lung adenocarcinoma after targeted therapy using a tyrosine kinase inhibitor

S. Kim, Hyung-Jin Kim, J. Cha, 2023, Medicine.